retatrutide phase 2 trial obesity nejm 2023 Another Promising Medication (Retatrutide) for This data from Phase 3

Many providers recommend against semaglutide during breastfeeding out of caution, particularly in the early months when breastfeeding is being established and infant exposure would be highest

Some estimates suggest up to 25% of adults have some level of needle anxiety, which makes a daily drop or a patch sound like an easier alternative

The supplement stack for transition Certain supplements can support the transition off GLP-1 medications

While Novo Nordisk, the manufacturer of certain branded semaglutide drugs, may object, the FD&C Act has preempted the field such that patent infringement claims will not lie in these circumstances

In the Phase 2 trial published in the New England Journal of Medicine (2023), retatrutide was administered as a once-weekly subcutaneous injection using a structured dose-escalation schedule

Studies suggest that hair loss affects approximately 1 in 20 people taking GLP-1 medications, and while it is often temporary, it can be deeply distressing